IL159643A0 - Substituted urea neuropeptide y y5 receptor antagonists - Google Patents

Substituted urea neuropeptide y y5 receptor antagonists

Info

Publication number: IL159643A0
Authority: IL; Israel
Prior art keywords: receptor antagonists; substituted urea; neuropeptide; urea neuropeptide; substituted
Prior art date: 2001-07-26

Application number

IL15964302A

Other languages

English (en)

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-26

Filing date

2002-07-24

Publication date

2004-06-01

2002-07-24 Application filed by Schering Corp filed Critical Schering Corp

2004-06-01 Publication of IL159643A0 publication Critical patent/IL159643A0/xx

Links

101710151321 Melanostatin Proteins 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 title 1
239000004202 carbamide Substances 0.000 title 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
150000003672 ureas Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL15964302A 2001-07-26 2002-07-24 Substituted urea neuropeptide y y5 receptor antagonists IL159643A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30843301P	2001-07-26	2001-07-26
PCT/US2002/023552 WO2003009845A1 (en)	2001-07-26	2002-07-24	Substituted urea neuropeptide y y5 receptor antagonists

Publications (1)

Publication Number	Publication Date
IL159643A0 true IL159643A0 (en)	2004-06-01

Family

ID=23193972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15964302A IL159643A0 (en)	2001-07-26	2002-07-24	Substituted urea neuropeptide y y5 receptor antagonists

Country Status (16)

Country	Link
US (2)	US6667319B2 (xx)
EP (1)	EP1418913A1 (xx)
JP (1)	JP2005500338A (xx)
CN (2)	CN1911913A (xx)
AR (1)	AR036191A1 (xx)
AU (1)	AU2002355286B2 (xx)
CA (1)	CA2454830C (xx)
HU (1)	HUP0401643A3 (xx)
IL (1)	IL159643A0 (xx)
IS (1)	IS7096A (xx)
MX (1)	MXPA04000707A (xx)
NZ (1)	NZ530429A (xx)
PE (1)	PE20030385A1 (xx)
PL (1)	PL368201A1 (xx)
TW (1)	TWI300064B (xx)
WO (1)	WO2003009845A1 (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
HU228621B1 (en) *	2001-09-24	2013-04-29	Univ Oregon Health & Science	Modification of feeding behavior
US8058233B2 (en)	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
US7166575B2 (en) *	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2004089296A2 (en)	2003-04-03	2004-10-21	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
US20090018092A1 (en)	2004-03-16	2009-01-15	The Regents Of The University Of California	Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
TW200630337A (en) *	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
ZA200703613B (en)	2004-10-20	2009-05-27	Univ California	Improved inhibitors for the soluble epoxide hydrolase
FR2884516B1 (fr) *	2005-04-15	2007-06-22	Cerep Sa	Antagonistes npy, preparation et utilisations
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
EP1909791A1 (en) *	2005-06-30	2008-04-16	Prosidion Limited	G-protein coupled receptor agonists
FR2894964B1 (fr) *	2005-12-19	2008-02-22	Cerep Sa	Composes a base de quatre cycles aromatiques, preparation et utilisations
TW200808723A (en)	2006-03-13	2008-02-16	Univ California	Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US8247442B2 (en)	2006-03-29	2012-08-21	Purdue Pharma L.P.	Benzenesulfonamide compounds and their use
US8937181B2 (en)	2006-04-13	2015-01-20	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
TW200815353A (en)	2006-04-13	2008-04-01	Euro Celtique Sa	Benzenesulfonamide compounds and their use
JP5207382B2 (ja) *	2006-08-30	2013-06-12	塩野義製薬株式会社	ウレア誘導体
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
WO2008124118A1 (en) *	2007-04-09	2008-10-16	Purdue Pharma L.P.	Benzenesulfonyl compounds and the use therof
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en)	2007-06-04	2013-10-02	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8765736B2 (en)	2007-09-28	2014-07-01	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
WO2009149279A2 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012054093A2 (en)	2010-01-29	2012-04-26	The Regents Of The University Of California	Acyl piperidine inhibitors of soluble epoxide hydrolase
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
BR122021002201A8 (pt)	2011-02-25	2023-04-11	Merck Sharp & Dohme	Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CN102675190A (zh) *	2012-05-23	2012-09-19	盛世泰科生物医药技术(苏州)有限公司	一种3-（二甲氨基）次甲基-n-甲磺酰基哌啶-4-酮的合成方法
EP2880028B1 (en)	2012-08-02	2020-09-30	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CA2898482A1 (en)	2013-02-22	2014-08-28	Linda L. Brockunier	Antidiabetic bicyclic compounds
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298A4 (en)	2016-12-20	2020-08-05	Merck Sharp & Dohme Corp.	ANTIDIABETIC SPIROCHROMAN COMPOUNDS
AU2019207887B2 (en)	2018-01-11	2024-05-23	Centaurus Therapeutics	Inhibitors of dihydroceramide desaturase for treating disease
WO2022076365A1 (en) *	2020-10-06	2022-04-14	Eastman Chemical Company	Aromatic enol ethers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2928485A1 (de)	1979-07-14	1981-01-29	Bayer Ag	Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4623662A (en)	1985-05-23	1986-11-18	American Cyanamid Company	Antiatherosclerotic ureas and thioureas
US5602024A (en)	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
IL139913A0 (en)	1998-06-08	2002-02-10	Schering Corp	Neuropeptide y5 receptor antagonists
CA2350714A1 (en)	1998-11-10	2000-05-18	Merck & Co., Inc.	Spiro-indolines as y5 receptor antagonists
MXPA03002263A (es) *	2000-09-14	2003-06-24	Schering Corp	Antagonistas de receptor de neuropeptido y y5 de urea sustituidos.

2002
- 2002-07-24 IL IL15964302A patent/IL159643A0/xx unknown
- 2002-07-24 MX MXPA04000707A patent/MXPA04000707A/es active IP Right Grant
- 2002-07-24 EP EP02752562A patent/EP1418913A1/en not_active Withdrawn
- 2002-07-24 CN CNA2006101215468A patent/CN1911913A/zh active Pending
- 2002-07-24 HU HU0401643A patent/HUP0401643A3/hu unknown
- 2002-07-24 WO PCT/US2002/023552 patent/WO2003009845A1/en active IP Right Grant
- 2002-07-24 JP JP2003515237A patent/JP2005500338A/ja active Pending
- 2002-07-24 CA CA002454830A patent/CA2454830C/en not_active Expired - Fee Related
- 2002-07-24 CN CNA028189647A patent/CN1558764A/zh active Pending
- 2002-07-24 NZ NZ530429A patent/NZ530429A/en unknown
- 2002-07-24 TW TW091116480A patent/TWI300064B/zh active
- 2002-07-24 AR ARP020102785A patent/AR036191A1/es unknown
- 2002-07-24 US US10/202,239 patent/US6667319B2/en not_active Expired - Fee Related
- 2002-07-24 AU AU2002355286A patent/AU2002355286B2/en not_active Ceased
- 2002-07-24 PE PE2002000653A patent/PE20030385A1/es not_active Application Discontinuation
- 2002-07-24 PL PL02368201A patent/PL368201A1/xx not_active Application Discontinuation
2003
- 2003-10-24 US US10/692,559 patent/US7304076B2/en not_active Expired - Fee Related
- 2003-12-31 IS IS7096A patent/IS7096A/is unknown

Also Published As

Publication number	Publication date
CA2454830C (en)	2010-02-02
US20030207860A1 (en)	2003-11-06
US20040102474A1 (en)	2004-05-27
HUP0401643A3 (en)	2009-06-29
US6667319B2 (en)	2003-12-23
CN1911913A (zh)	2007-02-14
JP2005500338A (ja)	2005-01-06
IS7096A (is)	2003-12-31
CA2454830A1 (en)	2003-02-06
PL368201A1 (en)	2005-03-21
PE20030385A1 (es)	2003-05-08
WO2003009845A1 (en)	2003-02-06
AU2002355286B2 (en)	2005-10-13
EP1418913A1 (en)	2004-05-19
WO2003009845A9 (en)	2004-03-11
CN1558764A (zh)	2004-12-29
MXPA04000707A (es)	2004-04-20
AR036191A1 (es)	2004-08-18
US7304076B2 (en)	2007-12-04
HUP0401643A2 (hu)	2004-12-28
TWI300064B (en)	2008-08-21
NZ530429A (en)	2005-09-30

Publication	Publication Date	Title
IL159643A0 (en)	2004-06-01	Substituted urea neuropeptide y y5 receptor antagonists
HK1054547A1 (zh)	2003-12-05	取代的脲神經肽yy5受體拮抗劑
IL156157A0 (en)	2003-12-23	Heteroaryl urea neuropeptide y y5 receptor antagonists
AU2002234056A1 (en)	2002-09-05	Heteroaryl urea neuropeptide Y Y5 receptor antagonists
IL149872A0 (en)	2002-11-10	Substituted imidazole neuropeptide y y5 receptor antagonists
IL139913A0 (en)	2002-02-10	Neuropeptide y5 receptor antagonists
AU6690001A (en)	2001-12-24	Thrombin receptor antagonists
AU2003251739A8 (en)	2004-01-23	New neuropeptide y y5 receptor antagonists
EP1254116A4 (en)	2003-04-23	ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
HK1064100A1 (en)	2005-01-21	Adenosine a 2a receptor antagonists
EP1351933A4 (en)	2005-09-07	ANTAGONISTS OF IL-8 RECEPTORS
EP1252162A4 (en)	2003-06-11	ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
AU9259801A (en)	2002-03-26	Alpha v integrin receptor antagonists
EP1359915A4 (en)	2004-07-21	UROTENSIN-II RECEPTOR ANTAGONISTS
PL362838A1 (en)	2004-11-02	Somatostatin antagonists
AU2002359524A8 (en)	2003-06-17	P2x7 receptor antagonists
IL156087A0 (en)	2003-12-23	Histamine receptor antagonists
PL370367A1 (en)	2005-05-16	Ccr-3 receptor antagonists v
AU9088401A (en)	2002-03-26	Alpha v integrin receptor antagonists
DE60134427D1 (de)	2008-07-24	Exzitatorische aminosäure-rezeptor-antagonisten
SE0003996D0 (sv)	2000-11-01	Receptorantagonister
SI1294714T1 (sl)	2007-12-31	Antagonisti trobinskega receptorja
NO20040339L (no)	2004-01-26	Nye neuropeptid Y Y5-reseptorantagonister.